PCI Biotech, a cancer-focused biopharmaceutical company, and RXi Pharmaceuticals, a biotechnology company focused on developing novel RNAi therapeutics for significant unmet needs, are extending their preclinical research collaboration initiated April 7, 2015. This extension is supported by a new preclinical research collaboration agreement that reflect RXi’s recently completed acquisition of MirImmune and PCI Biotech’s focus in oncology. In brief, the preclinical research collabo...